TABLE OF CONTENTS
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF THE GLOBAL TRANSFECTION REAGENTS AND EQUIPMENT MARKET 19
1.4 LIMITATIONS 23
1.5 MARKETS COVERED 23
2 MARKET SEGMENTATION 29
2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 CURRENCY AND PRICING 31
2.5 DBMR TRIPOD DATA VALIDATION MODEL 32
2.6 MULTIVARIATE MODELLING 35
2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE 35
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.9 DBMR MARKET POSITION GRID 37
2.10 MARKET APPLICATION COVERAGE GRID 38
2.11 VENDOR SHARE ANALYSIS 39
2.12 SECONDARY SOURCES 40
2.13 ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
4 PREMIUM INSIGHT 45
4.1 PESTEL 47
4.2 PORTER'S FIVE FORCES MODEL 48
5 INDUSTRY INSIGHTS: 49
6 GLOBAL TRANSFECTION REAGENTS AND EQUIPMENT MARKET, REGULATIONS 50
6.1 EUROPEAN UNION REGULATORY SCENARIO 50
6.2 U.S. REGULATORY SCENARIO 51
6.3 JAPAN REGULATORY SCENARIO 51
6.4 CHINA REGULATORY SCENARIO 52
7 MARKET OVERVIEW 54
7.1 DRIVERS 56
7.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES 56
7.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS 57
7.1.3 GROWING DEMAND FOR CHIMERIC GENES 57
7.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH 58
7.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS 58
7.2 RESTRAINTS 59
7.2.1 HIGH COST OF TRANSFECTION PRODUCTS 59
7.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS 59
7.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE 60
7.3 OPPORTUNITIES 60
7.3.1 EXPLORATION OF EMERGING MARKET 60
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 61
7.3.3 SURGING LEVEL OF INVESTMENT 62
7.4 CHALLENGES 62
7.4.1 LONG APPROVAL PROCEDURE 62
7.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS-ASSOCIATED TRANSFECTION 63
7.4.3 LACK OF TRAINED PROFESSIONALS 64
8 GLOBAL TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY PRODUCTS 65
8.1 OVERVIEW 66
8.2 REAGENTS & KITS 69
8.3 INSTRUMENTS 70
9 GLOBAL TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY STAGE 72
9.1 OVERVIEW 73
9.2 RESEARCH 76
9.3 PRECLINICAL 76
9.4 CLINICAL PHASES 77
9.5 COMMERCIAL 78
10 GLOBAL TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPE 80
10.1 OVERVIEW 81
10.2 TRANSIENT TRANSFECTION REAGENTS AND EQUIPMENT 84
10.3 STABLE TRANSECTION REAGENTS AND EQUIPMENT 84
11 GLOBAL TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY METHODS 86
11.1 OVERVIEW 87
11.2 NON-VIRAL METHODS 90
11.3 VIRAL METHODS 90
12 GLOBAL TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPES OF MOLECULE 92
12.1 OVERVIEW 93
12.2 PLASMID DNA 95
12.3 SMALL INTERFERING RNA (SIRNA) 96
12.4 PROTEINS 97
12.5 DNA OLIGONUCLEOTIDES 98
12.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS) 99
12.7 OTHERS 99
13 GLOBAL TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY ORGANISM 101
13.1 OVERVIEW 102
13.2 MAMMALIAN CELLS 104
13.3 PLANTS 105
13.4 FUNGI 106
13.5 VIRUS 107
13.6 BACTERIA 108
14 GLOBAL TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY APPLICATION 109
14.1 OVERVIEW 110
14.2 IN VITRO APPLICATION 112
14.2.1 IN VIVO APPLICATION 114
14.2.2 BIOPRODUCTION 115
14.2.3 OTHERS 115
14.2.4 SYNTHETIC BIOLOGY 116
14.2.5 AGRICULTURE 116
14.2.6 OTHERS 116
15 GLOBAL TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY END USER 117
15.1 OVERVIEW 118
15.2 BIOPHARMA 121
15.3 CROS 121
15.4 CMOS/CDMOS 122
15.5 ACADEMIA 123
15.6 HOSPITALS 124
15.7 CLINICAL LABS 125
15.8 OTHERS 126
16 GLOBAL TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL 127
16.1 OVERVIEW 128
16.2 DIRECT TENDER 131
16.3 RETAIL SALES 132
16.4 OTHERS 133
17 GLOBAL TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION 134
17.1 OVERVIEW 135
17.2 NORTH AMERICA 140
17.2.1 U.S. 145
17.2.2 CANADA 145
17.2.3 MEXICO 145
17.3 EUROPE 146
17.3.1 GERMANY 152
17.3.2 U.K. 152
17.3.3 FRANCE 152
17.3.4 ITALY 152
17.3.5 RUSSIA 152
17.3.6 SPAIN 152
17.3.7 TURKEY 152
17.3.8 NETHERLANDS 152
17.3.9 BELGIUM 152
17.3.10 SWITZERLAND 152
17.3.11 REST OF EUROPE 152
17.4 ASIA-PACIFIC 153
17.4.1 CHINA 158
17.4.2 JAPAN 158
17.4.3 INDIA 158
17.4.4 AUSTRALIA 158
17.4.5 SOUTH KOREA 158
17.4.6 SINGAPORE 158
17.4.7 THAILAND 158
17.4.8 MALAYSIA 158
17.4.9 INDONESIA 158
17.4.10 PHILIPPINES 158
17.4.11 REST OF ASIA-PACIFIC 158
17.5 SOUTH AMERICA 159
17.5.1 BRAZIL 164
17.5.2 ARGENTINA 164
17.5.3 REST OF SOUTH AMERICA 164
17.6 MIDDLE EAST AND AFRICA 165
17.6.1 SOUTH AFRICA 170
17.6.2 SAUDI ARABIA 170
17.6.3 U.A.E. 170
17.6.4 EGYPT 170
17.6.5 ISRAEL 170
17.6.6 REST OF MIDDLE EAST AND AFRICA 170
18 GLOBAL TRANSFECTION REAGENTS AND EQUIPMENT MARKET, COMPANY LANDSCAPE 171
18.1 COMPANY SHARE ANALYSIS: GLOBAL 171
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 172
18.3 COMPANY SHARE ANALYSIS: EUROPE 173
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 174
19 SWOT ANALYSIS 175
20 COMPANY PROFILE 176
20.1 THERMO FISHER SCIENTIFIC INC. 176
20.1.1 COMPANY SNAPSHOT 176
20.1.2 REVENUE ANALYSIS 176
20.1.3 COMPANY SHARE ANALYSIS 177
20.1.4 PRODUCT PORTFOLIO 177
20.1.5 RECENT DEVELOPMENT 178
20.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 179
20.2.1 COMPANY SNAPSHOT 179
20.2.2 REVENUE ANALYSIS 179
20.2.3 COMPANY SHARE ANALYSIS 180
20.2.4 PRODUCT PORTFOLIO 180
20.2.5 RECENT DEVELOPMENT 181
20.3 PROMEGA CORPORATION 182
20.3.1 COMPANY SNAPSHOT 182
20.3.2 COMPANY SHARE ANALYSIS 182
20.3.3 PRODUCT PORTFOLIO 183
20.3.4 RECENT DEVELOPMENT 183
20.4 TAKARA BIO INC. 184
20.4.1 COMPANY SNAPSHOT 184
20.4.2 REVENUE ANALYSIS 184
20.4.3 COMPANY SHARE ANALYSIS 185
20.4.4 PRODUCT PORTFOLIO 185
20.4.5 RECENT DEVELOPMENT 185
20.5 BIO-RAD LABORATORIES, INC. 186
20.5.1 COMPANY SNAPSHOT 186
20.5.2 REVENUE ANANLYSIS 186
20.5.3 COMPANY SHARE ANALYSIS 187
20.5.4 PRODUCT PORTFOLIO 187
20.5.5 RECENT DEVELOPMENT 188
20.6 ALTOGEN BIOSYSTEMS 189
20.6.1 COMPANY SNAPSHOT 189
20.6.2 PRODUCT PORTFOLIO 189
20.6.3 RECENT DEVELOPMENT 190
20.7 APPLIED BIOLOGICAL MATERIALS INC. (ABM) 191
20.7.1 COMPANY SNAPSHOT 191
20.7.2 PRODUCT PORTFOLIO 191
20.7.3 RECENT DEVELOPMENT 191
20.8 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC) 192
20.8.1 COMPANY SNAPSHOT 192
20.8.2 REVENUE ANALYSIS 192
20.8.3 PRODUCT PORTFOLIO 193
20.8.4 RECENT DEVELOPMENT 193
20.9 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER) 194
20.9.1 COMPANY SNAPSHOT 194
20.9.2 PRODUCT PORTFOLIO 194
20.9.3 RECENT DEVELOPMENT 194
20.10 CYTIVA 195
20.10.1 COMPANY SNAPSHOT 195
20.10.2 PRODUCT PORTFOLIO 195
20.10.3 RECENT DEVELOPMENT 195
20.11 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION) 196
20.11.1 COMPANY SNAPSHOT 196
20.11.2 REVENUE ANANLYSIS 196
20.11.3 PRODUCT PORTFOLIO 197
20.11.4 RECENT DEVELOPMENT 197
20.12 GENLANTIS INC. 198
20.12.1 COMPANY SNAPSHOT 198
20.12.2 PRODUCT PORTFOLIO 198
20.12.3 RECENT DEVELOPMENT 198
20.13 GENO TECHNOLOGY INC., USA 199
20.13.1 COMPANY SNAPSHOT 199
20.13.2 PRODUCT PORTFOLIO 199
20.13.3 RECENT DEVELOPMENT 199
20.14 GINKGO BIOWORKS 200
20.14.1 COMPANY SNAPSHOT 200
20.14.2 PRODUCT PORTFOLIO 200
20.14.3 RECENT DEVELOPMENTS 200
20.15 LONZA 201
20.15.1 COMPANY SNAPSHOT 201
20.15.2 REVENUE ANANLYSIS 201
20.15.3 PRODUCT PORTFOLIO 202
20.15.4 RECENT DEVELOPMENT 202
20.16 MAXCYTE, INC. 203
20.16.1 COMPANY SNAPSHOT 203
20.16.2 REVENUE ANALYSIS 203
20.16.3 PRODUCT PORTFOLIO 204
20.16.4 RECENT DEVELOPMENT 204
20.17 MERCK KGAA 205
20.17.1 COMPANY SNAPSHOT 205
20.17.2 REVENUE ANALYSIS 205
20.17.3 PRODUCT PORTFOLIO 206
20.17.4 RECENT DEVELOPMENT 206
20.18 MIRUS BIO LLC. 207
20.18.1 COMPANY SNAPSHOT 207
20.18.2 PRODUCT PORTFOLIO 207
20.18.3 RECENT DEVELOPMENT 207
20.19 ORIGENE TECHNOLOGIES, INC. 209
20.19.1 COMPANY SNAPSHOT 209
20.19.2 PRODUCT PORTFOLIO 209
20.19.3 RECENT DEVELOPMENT 209
20.20 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.) 210
20.20.1 COMPANY SNAPSHOT 210
20.20.2 REVENUE ANALYSIS 210
20.20.3 PRODUCT PORTFOLIO 211
20.20.4 RECENT DEVELOPMENT 211

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.